Coeptis Therapeutics Holdings, Inc. 8-K

What Happened

• Coeptis Therapeutics Holdings, Inc. (COEP) filed an 8-K (filed Jan 16, 2026) reporting that on Jan 12, 2026 Nasdaq's Listing Qualifications Department notified the company it is out of compliance with Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) for failing to hold its annual shareholder meeting within 12 months of its fiscal year end (Dec 31, 2024). The company previously disclosed an annual meeting scheduled for Jan 30, 2026 and believes holding that meeting will allow it to regain compliance.

Key Details

• Nasdaq letter dated Jan 12, 2026 cites violation of Listing Rules 5620(a) and 5810(c)(2)(G) (Annual Meeting Rule).
• Company has 45 calendar days from Jan 12, 2026 to submit a plan to Nasdaq to regain compliance.
• If Nasdaq accepts the plan, it may grant an exception of up to 180 days from the fiscal year end, meaning the compliance deadline could be extended through June 29, 2026.
• The company’s annual meeting is scheduled for Jan 30, 2026 (previously disclosed in its Jan 5, 2026 Form S-4 proxy/prospectus).

Why It Matters

• This is a compliance issue that can affect the company’s continued listing on Nasdaq if not resolved. The Jan 30, 2026 meeting is the key near-term event the company cites to regain compliance; investors should watch for confirmation that the meeting occurs and for any Nasdaq acceptance of a remediation plan or further notices. The 8-K also notes it contains forward-looking statements about the company’s ability to regain compliance.